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Metabolic reprogramming of muscle stem cells modulates myogenic cell fate. In this issue of Cell Stem Cell,
Ryall et al. (2015) show that SIRT1, a NAD+-dependent histone deacetylase, acts as an epigenetic regulator
that connects changes in satellite cell metabolism with changes in the transcriptional machinery toward
myogenic commitment.Skeletal muscle is a highly dynamic and
metabolically active tissue that can self-
repair in response to injury via the recruit-
ment of muscle stem cells called satellite
cells (SCs). Under normal conditions
SCs, identified by the expression of the
signature satellite cell marker paired box
transcription factor 7 (Pax7), reside in a
quiescent state between the basal lamina
and the sarcolemma of the muscle fibers.
Quiescent SCs have a low metabolic rate
and display few active mitochondria
and therefore are exposed to low levelsFigure 1. A Model on How Metabolic Reprogramming Promotes
Satellite Cell Activation in Adult Skeletal Muscle
In this issue of Cell Stem Cell, Ryall and colleagues (2015) suggest the contri-
bution of the NAD+-dependent SIRT1 deacetylase in promoting epigenetic
changes required for skeletal muscle stem cell (SC) activation during local
tissue injury and repair. In normal adult undamaged muscle tissue SCs are
quiescent; however, self-renewal and clonogenic capacity can be expanded
under experimental conditions where SIRT1 is activated, which include calo-
rie restriction (CR), sirtuin-activating compounds (STACs), and NAD+ gener-
ation via mitochondrial oxidative phosphorylation (OXPHOS). Inhibition of
SIRT1 deacetylase through depletion of NAD+ via active glycolysis, nicotin-
amide (NAM) treatment, or by genetic means alters epigenetic marks
(e.g., acetylation [Ac]) on histone and non-histone proteins. As a result, adult
SC activation occurs, and therefore promotes, muscle cell differentiation
through transcriptional regulation of target genes. The term C denotes cyto-
plasm, and N nucleus.of oxidative stress (Tang and
Rando, 2014). In response to
muscle damage or injury (hyp-
oxia, oxidative stress, inflam-
mation, exercise, and aging),
SCs become activated and
trigger cellular reprogramming
that results in enhanced prolif-
eration, differentiation, and/or
self-renewal (Figure 1). This
remodeling process is finely
coordinated by muscle-spe-
cific transcription factors that
include MyoD and myogenin
and is epigenetically controlled
by covalent modification of
DNA and histones, and non-
covalent mechanisms, such as
non-coding RNAs that regulate
gene expression at transcrip-
tional and post-transcriptional
levels (Segale´s et al., 2014). It
follows that SC activation re-
quires a shift in the cellular
metabolic state to better match
their functional needs, a pro-
cess referred as ‘‘metabolic re-
programming.’’ Understanding
the basic molecular mecha-nisms that govern myogenic stem cell
fate constitutes an active research area
with the aim of developing muscle
stem cell therapies to improve muscle
regeneration in a wide variety of neuro-
muscular disorders and age-related
sarcopenia.
In this issue of Cell Stem Cell, Ryall and
colleagues (2015) compare the transcrip-
tome of quiescent and proliferating
SCs and report that SC activation is
driven by a metabolic switch from fatty
acid oxidation to glycolysis. This meta-Cell Stem Cell 16bolic shift generates ATP while concomi-
tantly lowering the cellular level of NAD+.
In turn, reduced NAD+ levels contribute
to decreased nuclear SIRT1 deacetylase
activity toward histone H4 acetylation
at lysine 16 (H4K16). In a series of
comprehensive and elegant experiments,
the authors assess the role of SIRT1
in epigenetic regulation of SC fate.
SIRT1mKO mice, with muscle-specific
ablation of the SIRT1 catalytic domain,
display aberrant hyper-acetylation of his-
tone and non-histone protein targets,, February 5,leading to distinct programs
of gene expression in adult
SCs as they cycle through
quiescent and activated
states. Meanwhile, incuba-
tion of myogenic C2C12 cells
and SCs from single muscle
fibers with galactose instead
of glucose-containing media




ratio, with concomitant re-
duction in H4K16 acetylation
and MyoD expression in a
SIRT1-dependent manner.
Conversely, pharmacolog-
ical inhibition of SIRT1 with
nicotinamide leads to an
increase in H4K16 acetyla-
tion and MyoD expression.
The functional contribution
of SIRT1 to muscle growth
and differentiation is sup-
ported by the fact that
SIRT1mKO SCs induced to
differentiate in vitro under-
go premature differentiation2015 ª2015 Elsevier Inc. 103
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Previewswhen compared to SCs from WT litter-
mates. Of significance, SIRT1mKO mice
exhibit developmental defects and
impairedmuscle regeneration in response
to cardiotoxin-induced muscle injury.
Overall, this study highlights the role
of SIRT1 as a finely tuned biochemical
sensor of the SC metabolic state, sup-
porting earlier reports that place SIRT1
at the crossroad between nutrient/energy
homeostasis and cell fate signaling
in skeletal muscle (reviewed in Tonkin
et al., 2012). Summarily, this work
establishes that muscle SC activation
can be regulated by changes in cellular
metabolism, partly via reduction in
SIRT1-mediated H4K16 deacetylation
on the MyoD promoter. This is in agree-
ment with emerging literature propos-
ing a role for SIRT1 in the maintenance
of genomic and epigenetic compo-
nents in other stem cell populations
(Bosch-Presegue´ and Vaquero, 2014),
which represents an important homeo-
static control during normal aging and
diseases.
Altogether, these findings provide evi-
dence for the feasibility of targeting
SIRT1 as an effective therapeutic inter-
vention for the prevention or reversal of
age-related sarcopenia and other degen-
erative muscle disorders. Encouraging
results regarding the use of short-term
calorie restriction, a dietary manipulation
that increases SIRT1 activity (Cerletti104 Cell Stem Cell 16, February 5, 2015 ª201et al., 2012), and synthetic small-mole-
cule activators of SIRT1 (Mercken et al.,
2014) show muscle stem cell differentia-
tion and improved muscle quality in lab-
oratory animals (Figure 1). The age, sex,
and fiber-type differences in SC proper-
ties (Manzano et al., 2011) indicate the
need for additional studies aimed at
establishing the presence of alternative
mechanisms, if any, in the control of
muscle SC fate. It remains unclear
whether nuclear sirtuin members other
than SIRT1 also elicit epigenetic modi-
fications in response to changes in the
SCs’ metabolic state. A recent report
indicated that SIRT6 enhances glycolytic
flux and inhibits mitochondrial respira-
tion through interaction with hypoxia-
inducible factor-1a and increased H3K9
deacetylation (Zhong and Mostoslavsky,
2010), and both SIRT1 and SIRT6 pro-
teins orchestrate the metabolic reprog-
ramming of the human acute monocytic
leukemia cell line THP-1 in response to
acute inflammatory response (Liu et al.,
2012).
In closing, Ryall et al. provides a link
between metabolic reprogramming and
SC activation through modulation of
SIRT1 activity. The targeting of SIRT1-
mediated epigenetic actions may prevent
SCs dysfunction and would be an im-
portant strategy to achieve successful
treatments for degenerative muscle dis-
eases and sarcopenia.5 Elsevier Inc.ACKNOWLEDGMENTS
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